# OVID catalysts: Ovid Therapeutics Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/ovid/catalysts

> Ovid Therapeutics Inc. (OVID) has 2 upcoming catalysts. The next is the OV4071 topline data readout, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for OVID?

Ovid Therapeutics Inc. (OVID) has 2 upcoming catalysts. The next is the OV4071 topline data readout, Q1 2027. Press release filed with the SEC (EX-99): "Ovid anticipates reading out topline data in the first quarter of 2027." [Calendar and source filings](https://sec-api.dev/companies/ovid/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001628280-26-072494, https://www.sec.gov/Archives/edgar/data/1636651/000162828026072494/ovidexhibit9912026-q3.htm (retrieved 2026-11-12). Last confirmed 2026-11-10. Cite: https://sec-api.dev/companies/ovid/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Ovid Therapeutics Inc. |
| Ticker | OVID (Nasdaq) |
| SEC CIK | 1636651 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/ovid |

## Cash runway

Cash $161.4M as of 2026-09-30; quarterly burn $15.9M; about 30.5 months of runway at that rate (XBRL company facts, accession 0001628280-26-072495).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Dec 2022 | [OV329 trial start](https://sec-api.dev/pdufa/ov329) | OVID |  | completed | "In December 2022, we initiated a Phase 1 SAD/MAD study in healthy volunteers for OV329, a next-generation GABA-aminotransferase inhibitor." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1636651/000162828024046868/ovid-20240930.htm)) |
| July 1, 2024 | [GV101 topline data readout](https://sec-api.dev/pdufa/ov888) | OVID | cerebral cavernous malformations | completed, positive | "With Graviton, we announced positive topline data from a Phase 1 multiple-ascending dose study of OV888/GV101 on July 1, 2024 and originally intended to initiate a signal-finding trial in people living with cerebral cavernous malformations in the second half of 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1636651/000162828024046868/ovid-20240930.htm)) |
| March 10, 2025 | [Ovid Therapeutics Inc. earnings report](https://sec-api.dev/companies/ovid/catalysts) | OVID |  | completed | "Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636651/000162828025011839/ovid2024q4exhibit991.htm)) |
| May 13, 2025 | [Ovid Therapeutics Inc. earnings report](https://sec-api.dev/companies/ovid/catalysts) | OVID |  | completed | "Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636651/000162828025024911/ovid2025q1exhibit991.htm)) |
| Q3 2025 | [OV329 topline data readout](https://sec-api.dev/pdufa/ov329) | OVID |  | scheduled | "•Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636651/000162828025024911/ovid2025q1exhibit991.htm)) |
| Q4 2025 | [OV350 topline data readout](https://sec-api.dev/pdufa/ov350) | OVID |  | scheduled | "OV350 (Intravenous KCC2 direct activator) is currently being studied in healthy volunteers, with topline safety, tolerability and PK data anticipated in Q4 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636651/000119312525230409/d45212dex991.htm)) |
| October 2, 2025 | [OV329 topline data readout](https://sec-api.dev/pdufa/ov329) | OVID |  | completed, positive | "Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today announced positive topline results from its Phase 1 healthy volunteer study evaluating the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) activity of OV329, a next generation GABA-aminotransferase (GABA-AT) inhibitor being developed for drug-resistant epilepsies." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636651/000119312525230409/d45212dex991.htm)) |
| November 12, 2025 | [Ovid Therapeutics Inc. earnings report](https://sec-api.dev/companies/ovid/catalysts) | OVID |  | completed | "Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636651/000163665125000011/ovidexhibit9912025-q3.htm)) |
| March 17, 2026 | [OV4071 earnings report](https://sec-api.dev/pdufa/ov4071) | OVID |  | completed | "Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636651/000162828026019045/ovidexhibit9912025_x10-k.htm)) |
| Q2 2026 | [OV329 trial start](https://sec-api.dev/pdufa/ov329) | OVID |  | scheduled | "Ovid is engaged in regulatory conversations and currently anticipates initiating the Phase 2 study in the second quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636651/000162828026019045/ovidexhibit9912025_x10-k.htm)) |
| Q2 2026 | [OV4071 trial start](https://sec-api.dev/pdufa/ov4071) | OVID |  | scheduled | "OV4071 (Oral KCC2 direct activator) Ovid is completing an enabling package for its first oral KCC2 development candidate, OV4071, and intends to file for regulatory clearance in Q1 2026 and initiate a Phase 1/1b SAD/MAD study in Q2 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636651/000119312525230409/d45212dex991.htm)) |
| November 10, 2026 | [Ovid Therapeutics Inc. earnings report](https://sec-api.dev/companies/ovid/catalysts) | OVID |  | completed | "Ovid Therapeutics Reports Business Updates and Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636651/000162828026072494/ovidexhibit9912026-q3.htm)) |
| Q1 2027 | [OV4071 topline data readout](https://sec-api.dev/pdufa/ov4071) | OVID |  | scheduled | "Ovid anticipates reading out topline data in the first quarter of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636651/000162828026072494/ovidexhibit9912026-q3.htm)) |
| Q1 2027 | [OV329 topline data readout](https://sec-api.dev/pdufa/ov329) | OVID |  | scheduled | "The study is enrolling, and Ovid anticipates reading out topline data in the first quarter of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636651/000162828026072494/ovidexhibit9912026-q3.htm)) |

## Drugs

- [OV329](https://sec-api.dev/pdufa/ov329): 
- [OV350](https://sec-api.dev/pdufa/ov350): 
- [OV4071](https://sec-api.dev/pdufa/ov4071): 
- [GV101](https://sec-api.dev/pdufa/ov888): cerebral cavernous malformations

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/ovid/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "OVID catalysts: Ovid Therapeutics Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/ovid/catalysts

```bibtex
@misc{secapidev_companies_ovid_catalysts_20261116,
  title        = {OVID catalysts: Ovid Therapeutics Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/ovid/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_ovid_catalysts_20261116","title":"OVID catalysts: Ovid Therapeutics Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/ovid/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
